Publications
2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015
2026
Articles in international journals
- Nick P, Studnicka M, Gregor J, et al. Hospitalisations in patients with idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry and EMPIRE Registry. ERJ Open Research 2026; 12(1): 00402-2025.
2025
Articles in international journals
- Dimic-Janjic S, Stjepanovic M, Belic S, et al. Clinical Characteristics and Survival of Patients with Idiopathic Pulmonary Fibrosis: Analysis of the Serbian Cohort from the EMPIRE Registry. Diagnostics (Basel) 2025; 15(17): 2121.
- Jovanovic D, Mogulkoc N, Šterclová M, et al. Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosis. Journal of Thoracic Disease 2025; 17(12): ):10908-10923.
- Tóth NM, Kramer MR, Šterclová M, et al. Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients in the European MultiPartner IPF Registry: Challenges for Health Equity. Biomedicines 2025;13(11): 2684.
Presentations at international conferences
- Koziar Vašáková M, Gregor J, Mogulkoc N, et al. Modelling of Overall Survival of IPF Patients With Different Phenotypes Treated With Nintedanib. International Conference of the American-Thoracic-Society (ATS) 2025, 16–21/5/2025, San Francisco.
2024
Articles in international journals
- Koziar Vašáková M, Gregor J, Mogulkoc N, et al. Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: a retrospective registry-based study. Respiratory Medicine 2024; 234: 107791.
- Gregor J, Adir Y, M, Šterclová M, et al. The impact of switching to a second antifibrotic in patients with idiopathic pulmonary fibrosis: a retrospective multicentre study from the EMPIRE registry. Archivos de Bronconeumología 2024; 60(2): 80-87.
2023
Articles in international journals
- Štefániková M, Doubková M, Ovesná P, Šterclová M, Lacina L, Žurková M, et al. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry. BMC Pulmonary Medicine 2023; 23(1): 154.
Presentations at international conferences
- Koziar Vašáková M, Šterclová M, Moğulkoç N, Kramer M, Doubková M, Plačková M, et al. The impact of switching to a second antifibrotic therapy on outcomes in patients with IPF in the EMPIRE registry treated with pirfenidone or nintedanib. Lecture and e-poster at the ATS International Conference 2023, 19–24/5/2023, Washington DC.
- Lang D, Lamprecht B, Mogulkoc N, Sterclova M, Lewandowska K, Kramer et al. Clinical Characteristics and Survival According to the Presence of Velcro Crackles in the European Multipartner IPF Registry (EMPIRE). Poster presentation at the ATS International Conference 2023, 19–24/5/2023, Washington DC.
2022
Articles in international journals
- Májek O, Gregor J, Moğulkoç N, Lewandowska K, Šterclová M, Müller V, et al. Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone. PLoS ONE 2022; 17(9): e0273854.
- Nagy T, Toth NM, Palmer E, Polivka L, Csoma B, Nagy A, Clinical predictors of lung-function decline in systemic-sclerosis-associated interstitial lung disease patients with normal spirometry. Biomedicines 2022; 10(9): 2129.
- Jovanovic DM, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study. Respiratory Research 2022; 23(1): 135.
Presentations at international conferences
- Koziar Vašáková M, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Kramer M, et al. Long-term effect of nintedanib treatment of idiopathic pulmonary fibrosis in 11 countries of Europe and Asia . Poster presentation at the ERS International Congress 2022, 4–6/9/2022, Barcelona.
2021
Articles in international journals
- Kolonics-Farkas A, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. Differences in baseline characteristics and access to treatment of newly diagnosed patients With IPF in the EMPIRE countries. Frontiers in Medicine 2021; 8: 729203.
- Doubková M, Kriegová E, Littnerová S, Schneiderová P, Šterclová M, Bartoš V, et al. DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study. Therapeutic Advances in Respiratory Disease 2021; 15: 17534666211042529.
Presentations at international conferences
- Vašáková M, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M., et al. Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Poster presentation at the ERS International Congress 2021, 5–8/9/2021, virtual conference.
2020
Articles in international journals
- Kolonics-Farkas A, Šterclová M, Moğulkoç N, Kus J, Hájková M, Müller V, Jovanovic D, Tekavec-Trkanjec J, Littnerová S, Hejduk K, Vašáková M. Anticoagulant use and bleeding risk in Central European patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotic therapy: real-world data from EMPIRE. Drug Safety 2020; 43(10): 971–980. Times cited: 3 (Web of Science), 3 (Scopus)
- Tran T, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, Kramer MR, Jovanović D, Tekavec-Trkanjec J, Studnicka M, Stoeva N, Hejduk K, Dušek L, Suissa S, Vašáková M. The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research 2020; 21: 11. Times cited: 19 (Web of Science), 17 (Scopus)
Presentations at international conferences
- Jovanović DM, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. The effect of metformin on clinically relevant outcomes in 3,144 IPF patients from the EMPIRE registry. Poster presentation at the ERS International Congress 2020, 6–9/9/2020, virtual conference.
- Jovanović DM, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry. Poster presentation at the ERS International Congress 2020, 6–9/9/2020, virtual conference.
- Vašáková M, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. Pirfenidone effectiveness in idiopathic pulmonary fibrosis with different radiologic patterns. Poster presentation at the American Thoracic Society 2020 International Conference, 15–20/5/2020, Philadelphia.
2019
Articles in international journals
- Barczi E, Starobinski L, Kolonics-Farkas A, Eszes N, Bohacs A, Vašáková M, et al. Long-term effects and adverse events of nintedanib therapy in idiopathic pulmonary fibrosis patients with functionally advanced disease. Advances in Therapy 2019; 36(5): 1221–1232. Times cited: 5 (Web of Science), 6 (Scopus)
- Žurková M, Eva Kriegová E, Kolek V, Lošťáková V, Šterclová M, Bartoš M, et al. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respiratory Research 2019; 20: 16. Times cited: 38 (Web of Science), 37 (Scopus)
Presentations at international conferences
- Vašáková M, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, Jovanovic D, Tekavec-Trkanjec J, Kramer M, Studnicka M, Stoeva N, Littnerová S, Hejduk K, Dušek L. Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidon or nintedanib or their switch. Real world data from the EMPIRE registry.
Poster presentation at the ERS International Congress 2019, 28/9–2/10 2019, Madrid - Moğulkoç N, Tas MN, Kabasakal Y, Bishop PW, Littnerová S, Hejduk K, Vašáková M. Differences between ANCA positive and negative lung fibrosis cases without vasculitis.
Poster presentation at the ERS International Congress 2019, 28/9–2/10 2019, Madrid - Vašáková M. EMPIRE registry.
Oral presentation at the 5th Central & Eastern European IPF Platform Workshop, 1/4/2019, Geneva
2018
Articles in international journals
- Doubková M, Švancara J, Svoboda M, Šterclová M, Bartoš V, Plačková M, et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. The Clinical Respiratory Journal 2018; 12(4): 1526–1535. Times cited: 24 (Web of Science), 29 (Scopus)
Presentations at international conferences
- Kolonics-Farkas AM, Šterclová M, Mogulkoc N, Kus J, Müller V, Hájková M, et al. Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE)
Poster presentation at the ERS International Congress 2018, 15–19/9/2018, Paris - Mogulkoc N, Šterclová M, Müller V, Kus J, Hájková M, Jovanović DM, et al. Does body mass index have prognostic significance for patients with idiopathic pulmonary fibrosis?
Poster presentation at the ERS International Congress 2018, 15–19/9/2018, Paris - Müller V, Šterclová M, Mogulkoc N, Kus J, Hájková M, Jovanović DM, et al. Differences in baseline characteristics of newly diagnosed IPF patients in the EMPIRE countries.
Poster presentation at the ERS International Congress 2018, 15–19/9/2018, Paris - Vašáková M, Šterclová M,, Mogulkoc N, Kus J, Müller V, Hájková M, et al. Real world idiopathic pulmonary fibrosis in the EMPIRE registry.
Poster presentation at the ERS International Congress 2018, 15–19/9/2018, Paris - Vašáková M, Schneiderová P, Kolek V, Šterclová M, Lošťáková V, Žurková M, et al. Genetic background of idiopathic pulmonary fibrosis in the Czech Republic. American Journal of Respiratory and Critical Care Medicine 2018; 197: A5746.
Poster presentation at the American Thoracic Society 2018 International Conference, 18–23/5/2018, San Diego - Müller V. Learnings from IPF Registries in CEE – Is the diagnosis rate low? literature vs EMPIRE registry. Where the patients get lost? Solutions.
Oral presentation at the 4th Central & Eastern European IPF Platform Workshop, 17/4/2018, Budapest - Vašáková M. Patients portrait and diagnostic approach in CEE.
Oral presentation at the 4th Central & Eastern European IPF Platform Workshop, 17/4/2018, Budapest - Vašáková M. Real world: nintedanib in IPF
Oral presentation at the 4th Central & Eastern European IPF Platform Workshop, 17/4/2018, Budapest
2017
Articles in national journals
- Vašáková M. Idiopatická plicní fibróza: umíme ji vždy správně diagnostikovat a léčit? [Idiopathic pulmonary fibrosis. Can we always diagnose and treat it right?] Vnitřní lékařství 2017; 63(11): 796–801.
Presentations at international conferences
- Jovanović DM, Mogulkoc N, Šterclová M, Zolnowska B, Bartoš V, Plačková M, et al. Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry. European Respiratory Journal 2017; 50 (Suppl 61): OA1953.
Oral presentation at the ERS International Congress 2017, 9–13/9/2017, Milan
Times cited: 1 (Web of Science) - Lewandowska KB, Kus J, Zolnowska B, Sobiecka M, Martusewicz-Boros M, Sliwinski P, et al. Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry. European Respiratory Journal 2017; 50 (Suppl. 61): PA855.
Poster presentation at the ERS International Congress 2017, 9–13/9/2017, Milan - Müller V, Mogulkoc N, Šterclová M, Zolnowska B, Bartoš V, Plačková M, et al. Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? European Respiratory Journal 2017; 50 (Suppl. 61): PA3821.
Poster presentation at the ERS International Congress 2017, 9–13/9/2017, Milan - Vašáková M, Mogulkoc N, Šterclová M, Zolnowska B, Bartoš V, Plačková M, et al. Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real-world results from the EMPIRE registry. European Respiratory Journal 2017; 50 (Suppl 61): PA4880.
Poster presentation at the ERS International Congress 2017, 9–13/9/2017, Milan - Vašáková M. Pathogenesis of hypersensitivity pneumonitis (HP) – current concepts.
Oral presentation at the ERS International Congress 2017, 9–13/9/2017, Milan - Vašáková M. What did we learn about IPF management in some CEE counties? First results of IPF registry EMPIRE.
Oral presentation at the 3rd Central & Eastern European IPF Platform Workshop, 24/3/2017, Krakow - Kuś J.Practical approach to differential diagnosis of IPF.
Oral presentation at the 3rd Central & Eastern European IPF Platform Workshop, 24/3/2017, Krakow - Beunders I, Šterclová M. Patient advocacy groups in CEE: CIPFAPANET.
Oral presentation at the 3rd Central & Eastern European IPF Platform Workshop, 24/3/2017, Krakow
2016
Articles in national journals
- Doubková M, Uher M, Bartoš V, Šterclová M, Lacina L, Lošťáková V, et al. Prognostické faktory idiopatické plicní fibrózy (IPF) – analýza Českého registru IPF [Idiopathic pulmonary fibrosis prognostic factors - analysis of the Czech registry]. Časopis lékařů českých 2016; 155(4): 188–194.
Presentations at international conferences
- Vašáková M, Šterclová M, Bartoš J, Doubková M, Plačková M, Žurková M, et al. Do typical and atypical HRCT patterns make difference in prognosis of patients with IPF? European Respiratory Journal 2016; 48 (Suppl 60): PA795.
Poster presentation at the ERS International Congress 2016, 3–7/9/2016, London - Vašáková M, Šterclová M, Kus J, Bartoš J, Hájková M, Doubková M, et al. Does early diagnosis of idiopathic pulmonary fibrosis matter? Real-world’s data from the EMPIRE registry. European Respiratory Journal 2016; 48 (Suppl. 60): PA794.
Poster presentation at the ERS International Congress 2016, 3–7/9/2016, London - Žurková M, Kolek V, Lošťáková V, Kriegová E, Šterclová M, Bartoš V, et al. The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry. European Respiratory Journal 2016; 48 (Suppl. 60): PA2087.
Poster presentation at the ERS International Congress 2016, 3–7/9/2016, London - Vašáková M. Registry of idiopathic pulmonary fibrosis patients (PG course)
Oral presentation at the ERS International Congress 2016, 3–7/9/2016, London - Vašáková M. Current approach to diagnosis – how multi-disciplinary team (MDT) works?
Oral presentation at the 2nd Central & Eastern European IPF Platform Workshop, 11/3/2016, Prague - Kuś J. What has been changed in national recommendation and access to treatment (country presentation) – Poland?
Oral presentation at the 2nd Central & Eastern European IPF Platform Workshop, 11/3/2016, Prague - Müller V. What has been changed in national recommendation and access to treatment (country presentation) – Hungary?
Oral presentation at the 2nd Central & Eastern European IPF Platform Workshop, 11/3/2016, Prague - Šterclová M. How to get patients to the centers early? Educational programs.
Oral presentation at the 2nd Central & Eastern European IPF Platform Workshop, 11/3/2016, Prague
2015
Articles in national journals
- Žurková M, Neumannová K, Loštáková V, Tichý T, Kriegová E, Kolek V. Význam plicní rehabilitace u nemocných s idiopatickou plicní fibrózou [Effect of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis]. Studia pneumologica et phthiseologica 2015; 75(6): 213–218 .
Presentations at international conferences
- Vašáková M. IPF Registry.
Oral presentation at the Inaugural Central & Eastern European IPF Platform Workshop, 13–14/3/2015, Vienna - Müller V, Hájková M. IPF in the CEE Countries.
Oral presentation at the Inaugural Central & Eastern European IPF Platform Workshop, 13–14/3/2015, Vienna
Other outputs
- Vašáková M. Esbriet in IPF patients.
A lecture for AB in Krakow
The above-mentioned publications were supported by the company Boehringer Ingelheim.